- Home
- NRIX vs ECX Comparison
NRIX vs ECX Comparison
Compare NRIX & ECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- ECX
- Stock Information
- Founded
- NRIX 2009
- ECX 2017
- Country
- NRIX United States
- ECX China
- Employees
- NRIX N/A
- ECX N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- ECX EDP Services
- Sector
- NRIX Health Care
- ECX Technology
- Exchange
- NRIX Nasdaq
- ECX Nasdaq
- Market Cap
- NRIX 728.6M
- ECX 674.7M
- IPO Year
- NRIX 2020
- ECX N/A
- Fundamental
- Price
- NRIX $10.69
- ECX $2.29
- Analyst Decision
- NRIX Strong Buy
- ECX Strong Buy
- Analyst Count
- NRIX 14
- ECX 1
- Target Price
- NRIX $29.07
- ECX $3.20
- AVG Volume (30 Days)
- NRIX 1.2M
- ECX 1.3M
- Earning Date
- NRIX 10-09-2025
- ECX 11-06-2025
- Dividend Yield
- NRIX N/A
- ECX N/A
- EPS Growth
- NRIX N/A
- ECX N/A
- EPS
- NRIX N/A
- ECX N/A
- Revenue
- NRIX $88,381,000.00
- ECX $756,543,682.00
- Revenue This Year
- NRIX $74.59
- ECX $817.95
- Revenue Next Year
- NRIX N/A
- ECX $29.45
- P/E Ratio
- NRIX N/A
- ECX N/A
- Revenue Growth
- NRIX 41.86
- ECX 3.49
- 52 Week Low
- NRIX $8.18
- ECX $0.76
- 52 Week High
- NRIX $29.56
- ECX $3.25
- Technical
- Relative Strength Index (RSI)
- NRIX 63.25
- ECX 63.88
- Support Level
- NRIX $8.20
- ECX $2.08
- Resistance Level
- NRIX $10.23
- ECX $2.36
- Average True Range (ATR)
- NRIX 0.50
- ECX 0.15
- MACD
- NRIX 0.27
- ECX 0.01
- Stochastic Oscillator
- NRIX 99.80
- ECX 83.19
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About ECX ECARX Holdings Inc. Ordinary shares
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the People's Republic of China. The company's core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.